MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials

The Lancet Neurology

Volumn 12, Issue 7, 2013, Pages 669-676

  Sormani, Maria Pia ^a   Bruzzi, Paolo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOSIMILAR AGENT; GENERIC DRUG; GLATIRAMER;

ARTICLE; BRAIN DAMAGE; CLINICAL TRIAL (TOPIC); CORRELATIONAL STUDY; DOSE RESPONSE; FUNDING; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYSTEMATIC REVIEW; VALIDATION STUDY;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 84879017576     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70103-0     Document Type: Article

References (39)

1. Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis Committee for Medicinal Products for Human Use (CHMP), (accessed May 20, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133438.pdf.
2. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009, 65:268-275.
3. Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000, 1:49-67.
4. Sormani MP, Bruzzi P, Beckmann K, et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology 2003, 60:1462-1466.
5. Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 2011, 17:541-549.
6. Sormani MP, Bruzzi P, Comi G, Filippi M MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002, 58:417-421.
7. Sormani MP, Miller DH, Comi G, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001, 70:494-499.
8. Sormani MP, Signori A, Siri P, et al. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler 2013, 19:466-474.
9. Paty DW, Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
10. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Study Group.
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294. The Multiple Sclerosis Collaborative Research Group (MSCRG).
12. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998, 43:79-87. The Multiple Sclerosis Collaborative Research Group.
13. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
14. Li DK, Paty DW Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999, 46:197-206.
15. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999, 53:679-686. The Once Weekly Interferon for MS Study Group.
16. Comi G, Filippi M, Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001, 49:290-297. European/Canadian Glatiramer Acetate Study Group.
17. Filippi M, Wolinsky JS, Comi G Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006, 5:213-220. the CORAL Study Group.
18. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59:1507-1517.
19. Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double blind, dose comparison study of glatiramer acetate in relapsing remitting MS. Neurology 2007, 68:939-944.
20. Comi G, Cohen JA, Arnold DA, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 2011, 69:75-82.
21. De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci 2012, 312:97-101.
22. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
23. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012, 367:1087-1097.
24. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140.
25. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006, 66:894-900.
26. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
27. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472.
28. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
29. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
30. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365:1293-1303.
31. Comi G, Douglas J, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012, 366:1000-1009.
32. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367:1098-1107.
33. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
34. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1276.
35. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
36. Sormani MP, Li D, Bruzzi P, et al. Combined MRI lesions and relapses as a perfect surrogate for disability in multiple sclerosis. Neurology 2011, 77:1684-1690.
37. Renfro LA, Carlin BP, Sargent DJ Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics 2012, 68:258-267.
38. Giovane CD, Vacchi L, Mavridis D, Filippini G, Salanti G Network meta-analysis models to account for variability in treatment definitions: application to dose effects. Stat Med 2013, 32:25-39.
39. Miller DH, Barkhof F, Nauta JJ Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993, 116:1077-1094.